Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vidal Primiterio

Physician Assistant, Medical Lawrence, MA Physician Assistant

NPI 1861472987 CMS profile 10937079

25 Marston St, Suite 105, Lawrence, MA 01841

Open in the dashboard

General payments

$22,225

1,049 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vidal Primiterio of Lawrence, MA is reported in the CMS Open Payments database as having received $22,225 across 1,049 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,786 199
2024 General $4,248 210
2023 General $4,745 223
2022 General $4,306 210
2021 General $4,140 207

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vidal Primiterio
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Vidal Primiterio were reported at $4,786. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Vidal Primiterio Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,140 $156 $41–$563 $132
2022 $4,306 $185 $55–$649 $149
2023 $4,745 $199 $58–$717 $160
2024 $4,248 $206 $62–$740 $164
2025 $4,786 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,507 136 payments
  2. AbbVie, Inc. $2,545 162 payments
  3. Pfizer Inc. $1,531 72 payments
  4. Amgen Inc. $1,363 75 payments
  5. Novo Nordisk Inc $1,229 59 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $1,119 53 payments
  7. Janssen Pharmaceuticals, Inc $980 39 payments
  8. GlaxoSmithKline, LLC. $976 51 payments
  9. Lilly USA, LLC $724 28 payments
  10. Astellas Pharma US Inc $687 24 payments
  11. Other $7,564 350 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $22,036 1,045 payments
  2. Education $189 4 payments
Products named General payments · program years 2021–2025
  1. FARXIGA $1,538 65 payments
  2. Kerendia $1,119 53 payments
  3. NURTEC ODT $1,073 47 payments
  4. BREZTRI $1,065 39 payments
  5. RYBELSUS $1,050 57 payments
  6. ELIQUIS $1,019 46 payments
  7. XARELTO $980 39 payments
  8. TRELEGY ELLIPTA $930 48 payments
  9. Otezla $876 59 payments
  10. CREON $849 78 payments
  11. Other $16,960 844 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 155 drugs

Part D claims

14,428

Median for Physician Assistant: 241

Drug cost

$1,905,893

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 275 $322,009
Jardiance Empagliflozin Brand 180 $245,901
Linzess Linaclotide Brand 160 $176,276
Farxiga Dapagliflozin Propanediol Brand 115 $160,358
Trulicity Dulaglutide Brand 128 $157,132
Eliquis Apixaban Brand 104 $116,081
Xarelto Rivaroxaban Brand 81 $88,444
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 84 $74,603
Creon Lipase/Protease/Amylase Brand 47 $63,122
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 83 $58,008

The 10 drugs with the highest cost, of 155 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
$301 26 —
FARXIGA
$293 115 —
VOQUEZNA
$227 — —
REXULTI
$224 — —
ELIQUIS
$210 104 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,049 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record